Navamedic

Navamedic ASA: Annual Report 2024

Oslo, April 30 2025 - Navamedic ASA has today published its Annual Report for

2024. Find enclosed the report in PDF as well as an ESEF file version. The

report is also made available at the company's website at

https://navamedic.com/investors/annual-reports/

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Navamedic Mobile: +47 951 78 680 E-mail:

Lars Hjarrand, CFO, Navamedic Mobile: +47 917 62 842 E-mail:

About Navamedic:

Navamedic ASA is a Nordic pharmaceutical company dedicated to enhancing people's

quality of life by being a reliable supplier of high-quality prescription,

consumer health, and hospital products to hospitals and pharmacies. Our growing

product portfolio has been carefully selected to meet current public health

concerns, such as obesity, Parkinson's disease, antibiotics and metabolism, to

empower people to live healthier and more fulfilling lives. What sets us apart

is our deep-rooted commitment to understanding the needs and requirements of the

countries where we are present. Our local insight and competence enable us to

understand the specific needs of each country where we operate and ultimately to

gain market access. This makes us a preferred partner for international

companies expanding their footprint across the Nordics and Benelux regions,

through either in-licensing or out-licensing.

Navamedic has been listed on the Oslo Stock Exchange since 2006 (ticker: NAVA)

and is headquartered in Oslo, Norway.

For more information, please visit Navamedic.com.

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.

AI Terminal